MarketCap
Royalty Pharma plc RPRX
€ 58.07
-0.38%
Facebook
X
Telegram
Royalty Pharma plc Betriebsaufwand | RPRX
Betriebsaufwand Jährlich Royalty Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -829 M | 294 M | 638 M | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 638 M | -829 M | 34.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Ascendis Pharma A/S
ASND
|
761 M | $ 245.48 | 0.87 % | $ 14.9 B |  Danmark |
 |
Beam Therapeutics
BEAM
|
523 M | $ 23.79 | -1.08 % | $ 2.35 B |  USA |
 |
Benitec Biopharma
BNTC
|
51.2 M | $ 8.58 | -0.81 % | $ 399 M | USA |
 |
Capricor Therapeutics
CAPR
|
108 M | $ 5.72 | -3.54 % | $ 266 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cerus Corporation
CERS
|
149 M | $ 2.37 | 1.5 % | $ 452 M | USA |
 |
Cullinan Management
CGEM
|
242 M | $ 14.55 | 1.25 % | $ 877 M | USA |
 |
Curis
CRIS
|
33.9 M | $ 0.38 | -2.33 % | $ 5 M | USA |
 |
CorMedix
CRMD
|
126 M | $ 7.95 | 1.27 % | $ 573 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 14.37 | 3.53 % | $ 929 M | USA |
 |
NuCana plc
NCNA
|
25.7 M | $ 1.03 | 4.54 % | $ 11.6 B |  Britain |
 |
BioVie
BIVI
|
18.1 M | $ 1.33 | 7.26 % | $ 1.96 M | USA |
 |
CEL-SCI Corporation
CVM
|
24.8 M | $ 1.6 | -1.84 % | $ 12.8 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
86.2 M | $ 1.15 | -9.84 % | $ 60.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
700 M | $ 60.7 | -0.87 % | $ 7.29 M | USA |
 |
Daré Bioscience
DARE
|
14.3 M | $ 0.64 | -0.33 % | $ 7.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
153 M | $ 9.97 | 2.21 % | $ 1.39 B |  France |
 |
Denali Therapeutics
DNLI
|
555 M | $ 18.66 | 1.35 % | $ 3.22 B | USA |
 |
Precision BioSciences
DTIL
|
86.4 M | $ 6.4 | -3.61 % | $ 82.1 M | USA |
 |
Dyadic International
DYAI
|
10.1 M | $ 0.43 | 7.72 % | $ 15.6 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
15 M | $ 0.16 | -7.21 % | $ 7.31 M |  Israel |
 |
Enanta Pharmaceuticals
ENTA
|
168 M | $ 12.0 | 3.09 % | $ 256 K | USA |
 |
Entera Bio Ltd.
ENTX
|
11.5 M | $ 2.83 | -3.25 % | $ 131 M | Israel |
 |
Passage Bio
PASG
|
113 M | $ 3.36 | -0.33 % | $ 10.8 M | USA |
|
Forte Biosciences
FBRX
|
70.7 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Exelixis
EXEL
|
598 M | $ 65.14 | 0.95 % | $ 17.7 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Gilead Sciences
GILD
|
13.5 B | $ 158.71 | 1.71 % | $ 197 B | USA |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 7.91 | 4.56 % | $ 5.38 B |  Spain |
 |
GlaxoSmithKline plc
GSK
|
15.7 B | $ 51.12 | 0.73 % | $ 207 B | Britain |
 |
Halozyme Therapeutics
HALO
|
218 M | $ 128.07 | 1.94 % | $ 15.3 B | USA |
 |
Bio-Techne Corporation
TECH
|
547 M | $ 72.69 | 0.2 % | $ 11.3 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 36.84 | 1.97 % | $ 2.12 B | USA |
 |
Immuron Limited
IMRN
|
10.1 M | $ 0.96 | 0.25 % | $ 222 M |  Australia |
 |
Immunic
IMUX
|
103 M | $ 7.28 | -1.75 % | $ 1.13 B | USA |
 |
Immunovant
IMVT
|
533 M | $ 28.19 | -0.79 % | $ 5.14 B | USA |
 |
INmune Bio
INMB
|
47.4 M | $ 1.43 | -2.05 % | $ 35.4 M | USA |
 |
Insmed Incorporated
INSM
|
348 M | $ 93.44 | 0.05 % | $ 18.6 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
752 M | $ 43.42 | 1.13 % | $ 6.95 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.47 | -1.64 % | $ 132 M | France |
 |
Ironwood Pharmaceuticals
IRWD
|
287 M | $ 3.49 | 0.87 % | $ 565 M | USA |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 3.67 | -1.08 % | $ 219 M | France |
 |
Jazz Pharmaceuticals plc
JAZZ
|
1.39 B | $ 205.67 | -3.89 % | $ 12.5 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
37.3 B | $ 266.51 | 1.02 % | $ 642 B | USA |
 |
Kamada Ltd.
KMDA
|
69 K | $ 7.93 | 2.06 % | $ 457 M | Israel |
 |
Krystal Biotech
KRYS
|
228 M | $ 313.53 | 0.65 % | $ 9.07 B | USA |
 |
Kura Oncology
KURA
|
371 M | $ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
389 M | $ 114.86 | 3.7 % | $ 9.7 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
8.19 M | $ 1.0 | -0.1 % | $ 230 M | USA |